Oncology Corporate Profile
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|PEGPH20 (+ ABRAXANE® + Gemcitabine)||pegylated recombinant human hyaluronidase||Pancreatic cancer||III|
|PEGPH20 (+ eribulin)||pegylated recombinant human hyaluronidase||Breast cancer||I||Eisai|
|PEGPH20 (+ pembrolizumab)||pegylated recombinant human hyaluronidase||Gastric cancer||I|
|PEGPH20 (+ pembrolizumab)||pegylated recombinant human hyaluronidase||Non Small Cell Lung Cancer (NSCLC)||I|
View additional information on product candidates here »